The market is very small in the US and Europe, but possibly...

The market is very small in the US and Europe, but possibly revenue neutral in Asia, where the disease is more prevalent.

Comparing PI-88 to Avastin is unfair, with PI-88 now completely missing the endpoints on its first trial outside the liver cancer indication. It is worrysome that there is no detectable cancer-fighting activity, and this is strongly suggestive of Phase III failure, in my view. If the mechanism was sound for liver cancer, then some activity - any activity - would have been reported for lung cancer.

The future of PI-88 as a viable drug for multiple conditions is now dead. It is time to cut their losses, and try to find a lead that can actually generate meaningful revenue.

Strong sell.